Cytokines in terms of QSAR. Review, evaluation and comparative studies

References

• J. Tavernier, R. Devos, S. Cornelis, T. Tuypens, J. Van der Heyden, W. Fiers and G. Plaetinck, A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF, Cell 66, (1991), 1175–1184.
   PubMed Web of Science ®Google Scholar
• C. Sanderson, Interleukin-5, Eosinophils and Disease, Blood 79, (1992), 3101–3109.
   PubMed Web of Science ®Google Scholar
• J.A. Denburg, J.E. Silver and J.S. Abrams, Interleukin-5 is a human basophilopoietin: Induction of istamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors, Blood 77, (1991), 1462–1468.
   PubMed Web of Science ®Google Scholar
• Y. Yamagushi, T. Suda, S. Onta, K. Tominaga, Y. Miura and T. Kasahara, Analysis of the survival of mature human eosinophils: Interleukin-5 prevents apoptosis in mature human eosinophils, Blood 78, (1991), 2542–2547.
   PubMed Web of Science ®Google Scholar
• G.M. Walsh, A. Hartnell, A.J. Wardlaw, K. Kurihara, C.J. Sanderson and A.B. Kay, IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leukocyte integrin (CD 11/18)-dependent manner, Immunology 71, (1990), 258–265.
   PubMed Web of Science ®Google Scholar
• T. Fujisawa, R. Abu-Ghazaleh, H. Kita, C.J. Sanderson and G.J. Gleich, Regulatory effect of cytokines on eosinophil degranulation, J. Immunol. 144, (1990), 642–646.
   PubMed Web of Science ®Google Scholar
• E.J. Clutterbuck, E.M. Hirst and C.J. Sanderson, Human interleukin 5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6 and GMCSF, Blood 73, (1989), 1504–1512.
   PubMed Web of Science ®Google Scholar
• J. Corren, Anti-interleukin 5 antibody therapy in asthma and allergies, Curr. Opin. Allergy Clin. Immunology 11, (2011), 565–570.
   PubMed Web of Science ®Google Scholar
• R.P. Schleimer and B.S. Bochner, The effect of glucocorticoids on human eosinophils, J. Allergy Clin. Immunol. 94, (1994), 1202–1213.
   PubMed Web of Science ®Google Scholar
• H.M. Yang, H.R. Shin, S.H. Cho, G.Y. Song, I.J. Lee, M.K. Kim, S.H. Lee, J.C. Ryu, Y. Kim and S.H. Yung, The role of the hydrophobic group on ring A of chalcones in the inhibition of interleukin-5, Arch. Pharm. Res. 29, (2006), 969–976.
   PubMed Web of Science ®Google Scholar
• (a) H.M. Yang, H.R. Shin, S.H. Cho, S.C. Bang, G.Y. Song, J.H. Ju, M.K. Kim, S.H. Lee, J.C. Ryu, Y. Kim, and S.H. Jung, Structural requirement of chalcones for the inhibitory activity of interleukin-5, Bioorg. Med. Chem. 15 (2007), pp. 104–111; (b) 15th Hellenic Symposium on Medicinal Chemistry, QSAR of Interleukin inhibitors: a tool for anti-inflammatory drug design, 25–27 May 2012, Book of abstracts pp.130, poster 73.
   Google Scholar
• R. Devos, Y. Guisez, G. Plaetnick, S. Cornelis, J. Tavernier, J. Van der Heyden, L.H. Forey and J.E. Scheffler, Covalent modification of the interleukin-5 receptor by isothiazolones leads to inhibition of the binding of interleukin-5, Eur. J. Biochem. 225, (1994), 635–640.
   PubMedGoogle Scholar
• S.H. Jung, S.H. Cho, T.H. Dang, J.H. Lee, J.H. Ju, M.K. Kim, S.H. Lee, J.C. Ryu and Y. Kim, Structural requirements of isoflavonones for the inhibitory activity of interleukin-5, Eur. J. Med. Chem. 38, (2003), 537–545.
   PubMed Web of Science ®Google Scholar
• B. Min, S.R. Oh, H.K. Lee, K. Takatsu, I.M. Chang, K.R. Min and Y. Kim, Sophoricoside analogs as the IL-5 inhibitors from Sophora japonica, Planta Med. 65, (1999), 408–412.
   PubMed Web of Science ®Google Scholar
• P. Thanigaimalai, K.C. Lee, V.K. Sharma, J.H. Yun, Y. Kim and S.H. Jung, Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity, Bioorg. Med. Chem. 18, (2010), 4625–4629.
   PubMed Web of Science ®Google Scholar
• C. Joo, E. Venkateswararao, K.C. Lee, V.K. Sharma, M.S. Kyung, Y. Kim and S.H. Jung, Novel interleukin-5 inhibitors based on hydroxyethylaminomethyl-4H-chromen-4-one scaffold, Bioorg. Med. Chem. 20, (2012), 5757–5762.
   PubMed Web of Science ®Google Scholar
• P. Thanigaimalai, T.A. Le Hoang, K.C. Lee, V.K. Sharma, S.C. Bang, J.H. Yun, E. Roh, Y. Kim and S.H. Jung, Synthesis and evaluation of novel chromone analogs for their inhibitory activity against interleukin-5, Eur. J. Med. Chem. 45, (2010), 2531–2536.
   PubMed Web of Science ®Google Scholar
• P. Thanigaimalai, H.M. Yang, V.K. Sharma, Y. Kim and S.H. Jung, The scope of thallium nitrate oxidative cyclization of chalcones and evaluation of isoflavone and aurone analogs for their inhibitory activity against interleukin-5, Bioorg. Med. Chem. 18, (2010), 4441–4445.
   PubMed Web of Science ®Google Scholar
• J. Corren, Inhibition of Interleukin-5 for the treatment of eosinophilic diseases, Discov. Med. 13, (2012), 305–312.
   PubMed Web of Science ®Google Scholar
• T. Hirano, Interleukin 6 and its receptor: Ten years later, Int. Rev. Immunol. 16, (1998), 249–284.
   PubMed Web of Science ®Google Scholar
• S.C.R. Dominic, Seminars in Arthritis and Rheumatism, Vol. 38, Elsevier, Amsterdam, 2009, pp. 382-386.
   Google Scholar
• B. Handraskar, D.H. Mitchell, J.T. Colston and G.L. Freeman, Regulation of CCAAT/Enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion, Circulation 99, (1999), 427–433.
   PubMed Web of Science ®Google Scholar
• N. Rösler, I. Wichart and K.A. Jellinger, Intra vita lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer’s disease patients, Acta. Neurol. Scand. 103, (2001), 126–130.
   PubMed Web of Science ®Google Scholar
• M.M. Jahromi, B.A. Millward and A.G. Demaine, A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus, J. Interferon Cytokine Res. 20, (2000), 885–888.
   PubMed Web of Science ®Google Scholar
• B.P. Bandgar, S.A. Patil, J.V. Totre, B.L. Korbad, R.N. Gacche, B.S. Hote, S.S. Jalde and H.V. Chavan, Synthesis and biological evaluation of nitrogen-containing benzophenone analogues as TNF-alpha and IL-6 inhibitors with antioxidant activity, Bioorg. Med. Chem. Lett. 20, (2010), 2292–2296.
   PubMed Web of Science ®Google Scholar
• B.P. Bandgar, S.A. Patil, B.L. Korbad, S.H. Nile and C.N. Khobragade, Synthesis and biological evaluation of beta-chloro vinyl chalcones as inhibitors of TNF-alpha and IL-6 with antimicrobial activity, Eur. J. Med. Chem. 45, (2010), 2629–2633.
   PubMed Web of Science ®Google Scholar
• B.P. Bandgar and S.S. Gawande, Synthesis and biological screening of a combinatorial library of β-chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents, Bioorg. Med. Chem. Lett. 18, (2010), 2060–2065.
   Web of Science ®Google Scholar
• K. Upadhyay, A. Bavishi, S. Thakrar, A. Radadiya, H. Vala, S. Parekh, D. Bhavsar, M. Savant, M. Parmar, P. Adlakha and A. Shah, Synthesis and biological evaluation of 4-styrylcoumarin derivatives as inhibitors of TNF-a and IL-6 with anti-tubercular activity, Bioorg. Med. Chem. Lett. 21, (2011), 2547–2549.
   PubMed Web of Science ®Google Scholar
• R.H. Tale, A.H. Rodge, G.D. Hatnapure and A.P. Keche, The novel 3,4-dihydropyrimidin-2(1H)-one urea derivatives of N-aryl urea: synthesis, anti-inflammatory, antibacterial and antifungal activity evaluation, Bioorg. Med. Chem. Lett. 21, (2011), 4648–4651.
   PubMed Web of Science ®Google Scholar
• B.P. Bandgar, S.S. Gawande, R.G. Bodale, J.V. Totre and C.N. Khobragade, Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents, Bioorg. Med. Chem. Lett. 18, (2010), 1364–1370.
   Web of Science ®Google Scholar
• C. Chaulet, C. Croix, D. Alagille, S. Normad, A. Delwail, L. Favot, J.C. Lecron and M.C. Viaud-Massuard, Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors, Bioorg. Med. Chem. Lett. 21, (2011), 1019–1022.
   PubMed Web of Science ®Google Scholar
• S.B. Bharate, T.R. Mahajan, Y.R. Gole, M. Nambiar, T.T. Matan, A. Kulkarni-Almeida, S. Balachandran, H. Junjappa, A. Balakrishnan and R.A. Vishwakarma, Synthesis and evaluation of pyrazolo[3,4-b]pyridines and its structural analogues as TNF-α and IL-6 inhibitors, Bioorg. Med. Chem. Lett. 16, (2008), 7167–7176.
   Web of Science ®Google Scholar
• J.R. Tagat, S.W. McCombie, B.E. Barton, J. Jackson and J. Shortall, Synthetic inhibitors of interleukin-6 II: 3,5-diaryl pyridines and meta-terphenyls, Bioorg. Med. Chem. Lett. 5, (1995), 2143–2146.
   Web of Science ®Google Scholar
• B.P. Bandgar, S.A. Patil, B.L. Korbad, S.C. Biradar, S.N. Nile and C.N. Khobragade, Synthesis and biological evaluation of novel series of 2,2-bisaminomethylated aurone analogues as anti-inflammatory and antimicrobial agents, Eur. J. Med. Chem. 45, (2010), 3223–3227.
   PubMed Web of Science ®Google Scholar
• B.P. Bandgar, S.S. Gawande, R.G. Bodale, N.M. Gawande and C.N. Khobragade, Synthesis and biological evaluation of novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents, Bioorg. Med. Chem. 17, (2009), 8168–8173.
   PubMed Web of Science ®Google Scholar
• J.R. Tagat, D.V. Nazareno, S.W. McCombie, B.E. Barton, J. Shortall and J. Jackson, Synthetic inhibitors of interleukin-6 I: 2,3,7,8-tetrahydro-4-aryl-1H-cyclopent[e]imidazo[1,2-a]-pyridin-5(6H)-one and related compounds, Bioorg. Med. Chem. Lett. 5, (1995), 2139–2142.
   Web of Science ®Google Scholar
• T. Tanaka, M. Narazaki and T. Kishimoto, Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases, FEBS Letters 585, (2011), 3699–3709.
   PubMed Web of Science ®Google Scholar
• P.M. Murphy, M. Baggiolini, I.F. Charo, C.A. Hébert, R. Horuk, K. Matsushima, L.H. Miller, J.J. Oppenheim and C.A. Power, International Union of Pharmacology. XXII Nomenclature for chemokine receptors, Pharmacol. Rev. 52, (2000), 145–176.
   PubMed Web of Science ®Google Scholar
• B. Moser, M. Wolf, A. Walz and P. Loetsher, Chemokines: Multiple levels of leukocyte migration control, Trends Immunol. 25, (2004), 75–84.
   PubMed Web of Science ®Google Scholar
• D.E. Hu, Y. Hori and T.P. Fan, Interleukin-8 stimulates angiogenesis in rats, Inflammation 17, (1993), 135–143.
   PubMed Web of Science ®Google Scholar
• A.E. Koch, P.J. Polverini, S.L. Kunkel, L.A. Harlow, L.A. DiPietro, V.M. Elner, S.G. Elner and R.M. Strieter, Inteleukin-8 as a macrophage-derived mediator of angiogenesis, Science 258, (1992), 1798–1801.
   PubMed Web of Science ®Google Scholar
• R.M. Strieter, S.L. Kunkel, V.M. Elner, C.L. Martonyi, A.E. Koch, P.J. Polverini and S.G. Elner, Interleukin-8. A corneal factor that induces neovascularization, Am. J. Pathol. 141, (1992), 1279–1284.
   PubMed Web of Science ®Google Scholar
• A.E. Koch, M.V. Violin, J.M. Woods, S.L. Kunkel, M.A. Connors, L.A. Harlow, D.C. Woodruff, M.D. Burdick and R.M. Strieter, Regulation of angiogenesis by C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide-78 in the rheumatoid joint, Arthritis Rheum. 44, (2001), 31–40.
   PubMed Web of Science ®Google Scholar
• M.L. Guistizieri, F. Mascia, A. Frezzolini, O. DePità, L.M. Chinni, A. Giannetti, G. Girolomoni and S. Pastore, Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T-cell derived cytokines, J. Allergy Clin. Immunol. 107, (2001), 871–877.
   PubMed Web of Science ®Google Scholar
• N. Hirani, F. Antonicelli, R.M. Strieter, M.S. Wiesener, P.J. Ratcliffe, C. Haslett and S.C. Donnelly, The regulation of interleukin-8 by hypoxia in human macrophages—a potential role in the pathogenesis of the acute respiratory distress syndrome (ARDS), Mol. Med. 7, (2001), 685–697.
   PubMed Web of Science ®Google Scholar
• W.I. De Boer, J.K. Sont, A. Van Schadewijk, J. Stolk, J.H. Van Krieken and P.S. Hiemstra, Monocyte chemoattractant protein, interleukin 8 and chronic airways inflammation in COPD, J. Pathol. 190, (2000), 619–626.
   PubMed Web of Science ®Google Scholar
• J.J. Li, Small molecule interleukin-8 modulators, Expert Opin. Ther. Pat. 2001, United Kingdom, Vol. 11, No.12, pp. 1905–1910.
   Google Scholar
• W.E. Holmes, J. Lee, W.J. Kwang, G.C. Rice and W.I. Wood, Structure and functional expression of human interleukin-8 receptor, Science 253, (1991), 1278–1280.
   PubMed Web of Science ®Google Scholar
• P.M. Murphy and H.L. Tiffany, Cloning of complementary DNA encoding a functional human interleukin-8 receptor, Science 253, (1991), 1280–1283.
   PubMed Web of Science ®Google Scholar
• T. Yoshimura, K. Matsushima, J.J. Opppenheim and E.J. Leonard, Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: Partial characterization and separation from interleukin 1(IL 1), J. Immunol. 139, (1987), 788–793.
   PubMed Web of Science ®Google Scholar
• C.G. Larsen, A.O. Anderson, E. Appella, J.J. Oppenheim and K. Matsushima, The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes, Science 243, (1989), 1464–1466.
   PubMed Web of Science ®Google Scholar
• R.A. Warringa, L. Koenderman, P.T. Kok, J. Kreukniet and P.L. Bruinjzeel, Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3, Blood 77, (1991), 2694–2700.
   PubMed Web of Science ®Google Scholar
• M.V. White, T. Yoshimura, W. Hook, M.A. Kaliner and E.J. Leonard, Neutrophil attractant/activation protein-1 (NAP-1) causes human basophil histamine release, Immunol. Lett. 22, (1989), 151–154.
   PubMed Web of Science ®Google Scholar
• A. Walz, B. Dewald, V. Von Tscharner and M. Baggiolini, Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils, J. Exp. Med. 170, (1989), 1745–1750.
   PubMed Web of Science ®Google Scholar
• P. Peveri, A. Walz, B. Dewald and M. Baggiolini, A novel neutrophil-activating factor produced by human mononuclear phagocytes, J. Exp. Med. 167, (1988), 1547–1559.
   PubMed Web of Science ®Google Scholar
• E.J. Leonard, T. Yoshimura, S. Tanaka and M. Raffeld, Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1, J. Invest. Dermatol. 96, (1991), 690–694.
   PubMed Web of Science ®Google Scholar
• J.J. Li, K.G. Carson, B.K. Trivedi, W.S. Yue, Q. Ye, R.A. Glynn, S.R. Miller, D.T. Connor, B.D. Roth, J.R. Luly, J.E. Low, D.J. Heilig, W. Yang, S. Qin and S. Hunt, Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor, Bioorg. Med. Chem. 11, (2003), 3777–3790.
   PubMed Web of Science ®Google Scholar
• K.K. Ho, D.S. Auld, A.C. Bohnstedt, P. Conti, W. Dokter, S. Erickson, D. Feng, J. Inglese, C. Kingsbury, S.G. Kultgen, R.Q. Liu, C.M. Masterson, M. Ohlmeyer, Y. Rong, M. Rooseboom, A. Roughton, P. Samana, M.J. Smit, E. Son, J. Van der Louw, G. Vogel, M. Webb, J. Wijkmans, and M. You, Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists, Bioorg. Med. Chem. Lett. 16 (2006), pp. 2724–2728;
   Google Scholar
• Y. Wang, J. Busch-Petersen, F. Wang, L. Ma, W. Fu, J.K. Kerns, J. Jin, M.R. Palovich, J.K. Shen, M. Burman, J.J. Foley, D.B. Schmidt, G.E. Hunsberger, H.M. Sarau and K.L. Widdowson, 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists, Bioorg. Med. Chem. Lett. 17, (2007), 3864–3867.
   PubMed Web of Science ®Google Scholar
• G. Lai, J.R. Merritt, Z. He, D. Feng, J. Chao, M.F. Czarniecki, L.L. Rokosz, T.M. Stauffer, D. Rindgen and A.G. Taveras, Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists, Bioorg. Med. Chem. Lett. 18, (2008), 1864–1868.
   PubMed Web of Science ®Google Scholar
• C. Aki, J. Chao, J.A. Ferreira, M.P. Dwyer, Y. Yu, J. Chao, R.J. Merritt, G. Lai, M. Wu, R.W. Hipkin, X. Fan, W. Gonsiorek, J. Fossetta, D. Rindgen, J. Fine, D. Lundell, A.G. Taveras and P. Biju, Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region, Bioorg. Med. Chem. Lett. 19, (2009), 4446–4449.
   PubMed Web of Science ®Google Scholar
• M.P. Dwyer, Y. Yu, J. Chao, C. Aki, J. Chao, P. Biju, V. Girijavallabhan, D. Rindgen, R. Bond, R. Mayer-Ezel, J. Jakway, R.W. Hipkin, J. Fossetta, W. Gonsiorek, H. Bian, X. Fan, C. Terminelli, J. Fine, D. Lundell, J.R. Merritt, L.L. Rokosz, B. Kaiser, G. Li, W. Wang, T. Stauffer, L. Ozgur, J. Baldwin and A.G. Taveras, Discovery of 2-hydroxy-N, N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist, J. Med. Chem. 49, (2006), 7603–7606.
   PubMed Web of Science ®Google Scholar
• J.R. Merritt, L.L. Rokosz, K.H. Jr Nelson, B. Kaiser, W. Wang, T.M. Stauffer, L.E. Ozgur, A. Schilling, G. Li, J.J. Baldwin, A.G. Taveras, M.P. Dwyer and J. Chao, Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists, Bioorg. Med. Chem. Lett. 16, (2006), 4107–4110.
   PubMed Web of Science ®Google Scholar
• J. Chao, A.G. Taveras, J. Chao, C. Aki, M. Dwyer, Y. Yu, B. Purakkattle, D. Rindgen, J. Jakway, W. Hipkin, J. Fossetta, X. Fan, D. Lundell, J. Fine, M. Minnicozzi, J. Philips and J.R. Merritt, C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists, Bioorg. Med. Chem. Lett. 17, (2007), 3778–3783.
   PubMed Web of Science ®Google Scholar
• Y. Yu, M.P. Dwyer, J. Chao, C. Aki, J. Chao, B. Purakkattle, D. Rindgen, R. Bond, R. Mayer-Ezel, J. Jakway, H. Qiu, R.W. Hipkin, J. Fossetta, W. Gonsiorek, H. Bian, X. Fan, C. Terminelli, J. Fine, D. Lundell, J.R. Merritt, Z. He, G. Lai, M. Wu and A. Taveras, Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists, Bioorg. Med. Chem. Lett. 18, (2008), 1318–1322.
   PubMed Web of Science ®Google Scholar
• P. Biju, A.G. Taveras, M.P. Dwyer, Y. Yu, J. Chao, R.W. Hipkin, X. Fan, D. Rindgen, J. Fine and D. Lundell, Fluoroalkyl α side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists, Bioorg. Med. Chem. Lett. 19, (2009), 1431–1433.
   PubMed Web of Science ®Google Scholar
• S. Liu, Y. Liu, H. Wang, Y. Ding, H. Wu, J. Dong, A. Wong, S.H. Chen, G. Li, M. Chan, N. Sawyer, F.G. Gervais, M. Henault, S. Kargman, L.L. Bedard, Y. Han, R. Friesen, R.B. Lobell and D.M. Stout, Design, synthesis and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists, Bioorg. Med. Chem. Lett. 19, (2009), 5741–5745.
   PubMed Web of Science ®Google Scholar
• F. Hunt, C. Austin, R. Austin, R. Bonnert, P. Cage, J. Christie, M. Christie, C. Dixon, S. Hill, R. Jewell, I. Martin, D. Robinson and P. Willis, SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction, Bioorg. Med. Chem. Lett. 17, (2007), 2731–2734.
   PubMed Web of Science ®Google Scholar
• A. Baxter, A. Cooper, E. Kinchin, K. Moakes, J. Unitt and A. Wallace, Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists, Bioorg. Med. Chem. Lett. 16, (2006), 960–963.
   PubMed Web of Science ®Google Scholar
• P. Biju, A.G. Taveras, Y. Yu, J. Zheng, R.W. Hipkin, J. Fossetta, X. Fan, J. Fine and D. Lundell, 3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists, Bioorg. Med. Chem. Lett. 19, (2009), 1434–1437.
   PubMed Web of Science ®Google Scholar
• P. Biju, A. Taveras, Y. Yu, J. Zheng, J. Chao, D. Rindgen, J. Jakway, R.W. Hipkin, J. Fossetta, X. Fan, J. Fine, H. Qiu, J.R. Merritt and J.J. Baldwin, 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists, Bioorg. Med. Chem. Lett. 18, (2008), 228–231.
   PubMed Web of Science ®Google Scholar
• M.R. Sablone, M.C. Cesta, A. Moriconi, A. Aramini, C. Bizzarri, C. Di Giacinto, R. Di Bitondo, I. Gloaguen, M. Aschi, M. Crucianelli, R. Bertini and M. Allegretti, Structure-activity relationship of novel phenylacetic CXCR1 inhibitors, Bioorg. Med. Chem. Lett. 19, (2009), 4026–4030.
   PubMed Web of Science ®Google Scholar
• H. Nie, K.L. Widdowson, M.R. Palovich, W. Fu, J.D. Elliott, D.L. Bryan, M. Burman, D.B. Schmidt, J.J. Foley, H.M. Sarau and J. Busch-Petersen, N, N’-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors, Bioorg. Med. Chem. Lett. 16, (2006), 5513–5516.
   PubMed Web of Science ®Google Scholar
• M.P. Winters, C. Crysler, N. Subasinghe, D. Ryan, L. Leong, S. Zhao, R. Donatelli, E. Yurkow, M. Mazzulla, L. Boczon, C.L. Manthey, C. Molloy, H. Raymond, L. Murray, L. McAlonan and B. Tomczuk, Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides and sulfonylureas as novel antagonists of the CXCR2 receptor, Bioorg. Med. Chem. Lett. 18, (2008), 1926–1930.
   PubMed Web of Science ®Google Scholar
• Q. Jin, H. Nie, B.W. McCleland, K.L. Widdowson, M.R. Palovich, J.D. Elliot, R.M. Goodman, M. Burman, H.M. Sarau, K.W. Ward, M. Nord, B.M. Orr, P.D. Gorycki and J. Busch-Petersen, Discovery of potent and orally bioavailable N.N’-diarylurea antagonists for the CXCR2 chemokine receptor, Bioorg. Med. Chem. Lett. 14, (2004), 4375–4378.
   PubMed Web of Science ®Google Scholar
• M.A. Weidner-Wells, T.C. Henninger, S.A. Fraga-Spano, C.M. Boggs, M. Matheis, D.M. Ritchie, D.C. Argentieri, M.P. Wachter and D.J. Hlasta, Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists, Bioorg. Med. Chem. Lett. 14, (2004), 4307–4311.
   PubMed Web of Science ®Google Scholar
• B.W. McCleland, R.S. Davis, M.R. Palovich, K.L. Widdowson, M.L. Werner, M. Burman, J.J. Foley, D.B. Schmidt, H.M. Sarau, M. Rogers, K.L. Salyers, P.D. Gorycki, T.J. Roethke, G.J. Stelman, L.M. Azzarano, K.W. Ward and J. Busch-Peterson, Comparison of N.N’-diarylsquaramides and N, N’-diarylureas as antagonists of the CXCR2 chemokine receptor, Bioorg. Med. Chem. Lett. 17, (2007), 1713–1717.
   PubMed Web of Science ®Google Scholar
• N.S. Cutshall, R. Ursino, K.A. Kucera, J. Latham and N.C. Ihle, Nicotinamide N-Oxides as CXCR2 antagonists, Bioorg. Med. Chem. Lett. 11, (2001), 1951–1954.
   PubMed Web of Science ®Google Scholar
• A. Baxter, C. Bennion, J. Bent, K. Boden, S. Brough, A. Cooper, E. Kinchin, N. Kindon, T. McInally, M. Mortimore, B. Roberts and J. Unitt, Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists, Bioorg. Med. Chem. Lett. 13, (2003), 2625–2628.
   PubMed Web of Science ®Google Scholar
• M. Allegretti, R. Bertini, M.C. Cesta, C. Bizarri, R. Di Bitondo, V. Di Cioccio, E. Galliera, V. Berdini, A. Topai, G. Zampella, V. Russo, N. Di Bello, G. Nano, L. Nicolini, M. Locati, P. Fantucci, S. Florio and F. Colotta, 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors, J. Med. Chem. 48, (2005), 4312–4331.
   PubMed Web of Science ®Google Scholar
• J. Busch-Petersen, Q. Jin, B.W. McCleland, H. Nie, M.R. Palovich, R.S. Davis, W. Fu, J.D. Elliott, M. Burman, J.J. Foley, D.B. Schmidt, P. Podolin, B.J. Bolognese, D.C. Underwood, R.R. Osborn, C.J. Dehaas, M. Salmon, D.C. Carpenter, D.J. Killian, H.M. Sarau, and K.L. Widdowson, Small molecule antagonists for the CXCR2 chemokine receptor: N.N’-diarylureas and related series, 228th National Meeting of American Chemical Society, Philadelphia, PA, USA, Book of Abstracts, August 22–26, (2004); Abstract MEDI-192.
   Google Scholar
• P.L. Podolin, B.J. Bolognese, J.J. Foley, D.B. Schmidt, P.T. Buckley, K.L. Widdowson, Q. Jin, J.R. White, J.M. Lee, R.B. Goodman, T.R. Hagen, O. Kajikawa, L.A. Marshall, D.W. Hay and H.M. Sarau, A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit, J. Immunol. 169, (2002), 6435–6444.
   PubMed Web of Science ®Google Scholar
• C. Bizzarri, A.R. Beccari, R. Bertini, M.R. Cavicchia, S. Giorgini and M. Allegretti, ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets, Pharmacol. Ther. 112, (2006), 139–149.
   PubMed Web of Science ®Google Scholar
• A.S. Michaelidou and D. Hadjipavlou-Litina, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A comparative QSAR Study, Chem. Rev. 105, (2005), 3235–3271.
   PubMed Web of Science ®Google Scholar
• E. Pontiki and D. Hadjipavlou-Litina, Review in quantitative structure activity relationships on lipoxygenase inhibitors, Mini Rev. Med. Chem. 3, (2003), 487–499.
   PubMed Web of Science ®Google Scholar
• E. Pontiki and D. Hadjipavlou-Litina, Lipoxygenase inhibitors: A comparative QSAR study, review and evaluation of new QSARs, Med. Res. Rev. 28, (2008), 39–117.
   PubMed Web of Science ®Google Scholar
• M.T. Lindenmeyer, A. Hrenn, C. Kern, V. Castro, R. Murillo, S. Müller, S. Laufer, J. Schulte-Mönting, B. Siedle and I. Merfort, Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells, Bioorg. Med. Chem. 14, (2006), 2487–2497.
   PubMed Web of Science ®Google Scholar
• A.I. Khlebnikov, I.A. Schepetkin and M.T. Quinn, Quantitative structure-activity relationships for small non-peptide antagonists of CXCR2: Indirect 3D approach using the frontal polygon method, Bioorg. Med. Chem. 14, (2006), 352–365.
   PubMed Web of Science ®Google Scholar
• J.B. Ghasemi, P. Zohrabi and H. Khajehsharifi, Quantitative structure-activity relationship study of nonpeptide antagonists of CXCR2 using stepwise multiple linear regression analysis, Monatsh. Chem. 141, (2010), 111–118.
   Web of Science ®Google Scholar
• T. Asadollahi, S. Dadfarnia, A.M. Shabani, J.B. Ghasemi and M. Sarkhosh, QSAR models for CXCR2 receptor antagonists based on the genetic algorithm for data preprocessing prior to the application of the PLS linear regression method and design of the new compounds using in silico virtual screening, Molecules 16, (2011), 1928–1955.
   PubMed Web of Science ®Google Scholar
• L. Aureli, G. Cruciani, M.C. Cesta, R. Anacardio, L. De Simone and A. Moriconi, Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach, J. Med. Chem. 48, (2005), 2469–2479.
   PubMed Web of Science ®Google Scholar
• C. Hansch, A.J. Leo and W.R. Taft, A survey of Hammett substituent constants and resonance and field parameters, Chem. Rev. 91, (1991), 165–195.
   Web of Science ®Google Scholar
• S.H. Unger and C. Hansch, Quantitative models of steric effects, Prog. Phys. Org. Chem. 12, (1976), 91–114.
   Google Scholar
• C. Hansch and A. Leo, Exploring QSAR: Fundamentals and applications in chemistry and biology, American Chemical SocietyWashington, DC, 1995.
   Google Scholar
• C. Hansch, A. Leo and D. Hoekman, Exploring QSAR: Hydrophobic, Electronic, and Steric constants, American Chemical SocietyWashington, DC, 1995.
   Google Scholar
• C. Silippo and A. Vittoria, Comprehensive Medicinal Chemistry, in Three Dimensional Structure of Drugs, C. Hansch, P.G. Sammes and J.B. Taylor, eds., CA Ramsden Pergamon PressNew York, 1990.
   Google Scholar
• A. Verloop, The Sterimol approach to drug design, Marcell DeckerNew York, 1987.
   Google Scholar
• BioByte Corporation, C-QSAR database, 201 W Fourth Str., Suite # 204, Claremont CA 91711–4707, USA.
   Google Scholar
• M. Abraham and J.C. McGowan, The use of characteristic volumes to measure cavity terms in reversed phase liquid chromatography, Chromatographia 23, (1987), 243–246.
   Web of Science ®Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2!, J. Mol. Graph. Model. 20, (2002), 269–276.
   PubMed Web of Science ®Google Scholar
• C. Hwang, M. Gatanaga, G.A. Granger and T. Gatanaga, Mechanism of release of soluble forms of tumor necrosis factor/ lymphotoxin receptors by phorbol myristate acetate-stimulated human THP-1 cells in vitro, J. Immunol. 151, (1993), 5631–5638.
   PubMed Web of Science ®Google Scholar
• S. Qin, G. LaRosa, J.J. Campbell, H. Smith-Heath, N. Kassam, X. Shi, L. Zeng, E.C. Buthcher and C.R. Mackay, Expression of monocyte chemoattractant protein-1 and interleukin-8 receptors on subsets of T cells: Correlation with transendothelial chemotactic potential, Eur. J. Immunol. 26, (1996), 640–647.
   PubMed Web of Science ®Google Scholar
• A.S. Kraft and W.B. Anderson, Phorbol esters increase the amount of Ca2+, phospholipid-dependent protein kinase associated with plasma membrane, Nature 301, (1983), 621–623.
   PubMed Web of Science ®Google Scholar
• R. Austen, A. Baxter, R. Bonnert, F. Hunt, E. Kinchin, and P. Willis, Int. Patent Appl. WO 00/09511.
   Google Scholar
• W. Gonsiorek, X. Fan, D. Hesk, J. Fossetta, H. Qiu, J. Jakway, M. Billah, M. Dwyer, J. Chao, G. Deno, A. Taveras, D.J. Lundell and R.W. Hipkin, Pharmacological characterization of Sch527123, a potent CXCR1/CXCR2 antagonist, J. Pharmacol. Exp. Ther. 322, (2007), 477–485.
   PubMed Web of Science ®Google Scholar
• C. Hansch, A. Kurup, R. Garg and H. Gao, Chem-bioinformatics and QSAR: A review of QSAR lacking positive hydrophobic terms, Chem. Rev. 101, (2001), 619–672.
   PubMed Web of Science ®Google Scholar
• C. Hansch and T. Klein, Molecular graphics and QSAR in the study of enzyme-ligand interactions; on the definition of bioreceptors, Acc. Chem Res. 19, (1986), 392–400.
   Web of Science ®Google Scholar
• A.O. Aptula, N.G. Jeliazkova, T.W. Schultz and M.T.D. Cronin, The better predictive model: High q2 for the training set or low root mean square error of prediction for the test set?, QSAR Comb. Sci. 24, (2005), 385–396.
   Google Scholar
• J.G. Topliss and R.J. Costello, Chance correlations in structure–activity studies using multiple regression analysis, J. Med. Chem. 15, (1972), 1066–1068.
   PubMed Web of Science ®Google Scholar